WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='3.238.250.73'

WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SHOW FULL COLUMNS FROM `wp_clean_up_optimizer_ip_locations`

Algernon Pharmaceuticals Inc. AGN.CN / AGNPF - Pot Stocks Charts, Financials, Analysts Price Targets, Insiders Transactions

Algernon Pharmaceuticals Inc.

CNSX: AGN

Canadian symbol:	AGN.CN
US symbol:	AGNPF

Currency in CAD

Valuation Measures⁴

Market Cap (intraday)	4.78M
Enterprise Value	4.09M
Trailing P/E	N/A
Forward P/E	N/A
PEG Ratio (5 yr expected)	N/A
Price/Sales (ttm)	N/A
Price/Book (mrq)	1.08
Enterprise Value/Revenue	N/A
Enterprise Value/EBITDA	-0.61

Trading Information

Stock Price History

Beta (5Y Monthly)	0.29
52-Week Change ³	-79.33%
S&P500 52-Week Change ³	-11.09%
52 Week High ³	1.7375
52 Week Low ³	0.2950
50-Day Moving Average ³	0.4942
200-Day Moving Average ³	0.7821

Share Statistics

Avg Vol (3 month) ³	15.69k
Avg Vol (10 day) ³	25.1k
Shares Outstanding ⁵	9.65M
Implied Shares Outstanding ⁶	N/A
Float ⁸	8.17M
% Held by Insiders ¹	3.22%
% Held by Institutions ¹	14.40%
Shares Short (Mar 14, 2023) ⁴	7.46k
Short Ratio (Mar 14, 2023) ⁴	0.39
Short % of Float (Mar 14, 2023) ⁴	N/A
Short % of Shares Outstanding (Mar 14, 2023) ⁴	0.08%
Shares Short (prior month Feb 14, 2023) ⁴	5.29k

Dividends & Splits

Forward Annual Dividend Rate ⁴	N/A
Forward Annual Dividend Yield ⁴	N/A
Trailing Annual Dividend Rate ³	0.00
Trailing Annual Dividend Yield ³	0.00%
5 Year Average Dividend Yield ⁴	N/A
Payout Ratio ⁴	0.00%
Dividend Date ³	N/A
Ex-Dividend Date ⁴	N/A
Last Split Factor ²	4:1
Last Split Date ³	Mar 02, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends	Aug 30, 2022
Most Recent Quarter (mrq)	Nov 29, 2022

Profitability

Profit Margin	0.00%
Operating Margin (ttm)	0.00%

Management Effectiveness

Return on Assets (ttm)	-52.60%
Return on Equity (ttm)	-109.23%

Income Statement

Revenue (ttm)	N/A
Revenue Per Share (ttm)	N/A
Quarterly Revenue Growth (yoy)	N/A
Gross Profit (ttm)	N/A
EBITDA	N/A
Net Income Avi to Common (ttm)	-6.73M
Diluted EPS (ttm)	-0.7400
Quarterly Earnings Growth (yoy)	N/A

Balance Sheet

Total Cash (mrq)	689.7k
Total Cash Per Share (mrq)	0.07
Total Debt (mrq)	N/A
Total Debt/Equity (mrq)	N/A
Current Ratio (mrq)	0.59
Book Value Per Share (mrq)	0.47

Cash Flow Statement

Operating Cash Flow (ttm)	-4.06M
Levered Free Cash Flow (ttm)	-1.42M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.

Full screen

Warning: Use of undefined constant SITE_CONFIG_TWITTER_ACCOUNT - assumed 'SITE_CONFIG_TWITTER_ACCOUNT' (this will throw an Error in a future version of PHP) in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 10

Notice: Undefined variable: current_category_name in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 247

Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.

Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363

Notice: Undefined index: stockNewsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363

Warning: mysqli_fetch_assoc() expects parameter 1 to be mysqli_result, bool given in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 460

Company	News	Date

Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 710

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Currency in CAD

Earnings Estimate	Current Qtr. (Feb 2023)	Next Qtr. (May 2023)	Current Year (2023)	Next Year (2024)
No. of Analysts	1	1	1	1
Avg. Estimate	-0.11	-0.16	-0.67	-0.56
Low Estimate	-0.11	-0.16	-0.67	-0.56
High Estimate	-0.11	-0.16	-0.67	-0.56
Year Ago EPS	-0.08	0.12	0.87	-0.67

Revenue Estimate	Current Qtr. (Feb 2023)	Next Qtr. (May 2023)	Current Year (2023)	Next Year (2024)
No. of Analysts	1	1	1	1
Avg. Estimate	N/A	N/A	N/A	N/A
Low Estimate	N/A	N/A	N/A	N/A
High Estimate	N/A	N/A	N/A	N/A
Year Ago Sales	N/A	N/A	N/A	N/A
Sales Growth (year/est)	N/A	N/A	N/A	N/A

Earnings History	2021-08-30	2022-05-30	2022-08-30	2022-11-29
EPS Est.	-0.75	-0.23	-0.17	-0.16
EPS Actual	-0.08	0.12	0.3	-0.2
Difference	0.67	0.35	0.47	-0.04
Surprise %	89.30%	152.20%	276.50%	-25.00%

EPS Trend	Current Qtr. (Feb 2023)	Next Qtr. (May 2023)	Current Year (2023)	Next Year (2024)
Current Estimate	-0.11	-0.16	-0.67	-0.56
7 Days Ago	-0.11	-0.16	-0.67	-0.56
30 Days Ago	-0.46	-0.63	-2.69	-2.25
60 Days Ago	-0.46	-0.63	-2.69	-2.25
90 Days Ago	-0.46	-0.63	-2.69	-2.25

EPS Revisions	Current Qtr. (Feb 2023)	Next Qtr. (May 2023)	Current Year (2023)	Next Year (2024)
Up Last 7 Days	N/A	N/A	N/A	N/A
Up Last 30 Days	N/A	N/A	N/A	N/A
Down Last 7 Days	N/A	N/A	N/A	N/A
Down Last 30 Days	N/A	N/A	N/A	N/A

Growth Estimates	AGN.CN	Industry	Sector(s)	S&P 500
Current Qtr.	-37.50%	N/A	N/A	N/A
Next Qtr.	-233.30%	N/A	N/A	N/A
Current Year	-177.00%	N/A	N/A	N/A
Next Year	16.40%	N/A	N/A	N/A
Next 5 Years (per annum)	N/A	N/A	N/A	N/A
Past 5 Years (per annum)	N/A	N/A	N/A	N/A

Notice: Undefined variable: insiders_html in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/template-company-details.php on line 711

Insiders transactions are updated every hour.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Major Holders

Insider Roster

Insider Transactions

Major Holders

Currency in CAD

Breakdown

3.22%	% of Shares Held by All Insider
14.40%	% of Shares Held by Institutions
14.87%	% of Float Held by Institutions
2	Number of Institutions Holding Shares

AGN.CN Short Data (Canadian side):
https://shortdata.ca/stock/AGN.CN/
IIROC Consolidated Short Position Report

AGNPF Short Interest (US side):
https://fintel.io/s/us/AGNPF/
US Short Volume
FINRA OTC Equity Short Interest

Coming Soon

Search SEDAR Filings

Company Name:

Document Type:

Start Date:

End Date:

Press Releases by Algernon Pharmaceuticals Inc.

48 views0 min read

Algernon Pharmaceuticals subsidiary completes first dosing in Phase 1 clinical study of DMT

Algernon Pharmaceuticals

Vancouver --News Direct-- Algernon Pharmaceuticals Inc.Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or DMT.Moreau told Pro... Read More...

75 views0 min read

Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

Algernon Pharmaceuticals

Vancouver, BC --News Direct-- Algernon Pharmaceuticals Inc.Algernon Pharmaceuticals CEO Christopher Moreau said the company has announced that its subsidiary Algernon NeuroScience has dosed the first subject in the Phase 1 DMT clinical stroke study. Moreau told Proactive this dosing was in the Netherlands where the study is being conducte... Read More...

885 views4 min read

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Algernon Pharmaceuticals

VANCOUVER, British Columbia, July 07, 2022 -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its planned Phase 1 clinical human study of AP-188 (“N,N-dimethyltryptamine” or “DMT”). DMT ... Read More...

891 views5 min read

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

Algernon Pharmaceuticals

VANCOUVER, British Columbia, July 05, 2022 -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to disclose that as part of its intellectual property patent applications filed in early 2021 for AP-188 (“N,N-dimethyltryptami... Read More...

372 views4 min read

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals

VANCOUVER, British Columbia, Jan. 19, 2022 -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has filed a combined Clinical Trials of Investigational Medicinal Products and Ethics Approval application,... Read More...

144 views4 min read

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Algernon Pharmaceuticals

VANCOUVER, British Columbia, Dec. 08, 2021 -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“N,N-Dimethyltryptamine or ... Read More...

128 views4 min read

Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference

Algernon Pharmaceuticals

VANCOUVER, British Columbia, Sept. 09, 2021 -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that its CEO Christopher J. Moreau will be delivering the Keynote Presentation at the Microdose Virtual 2021 “The ... Read More...

134 views5 min read

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

Algernon Pharmaceuticals

VANCOUVER, British Columbia, Sept. 07, 2021 -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has confirmed in its own preclinical study, that AP-188 (“N,N-Dimethyltryptamine or “DMT”), increased the ... Read More...

Coming Soon.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Index	Last	% Change
S&P 500	4,027.81	1.42%Positive
Euro STOXX 50	4,231.27	1.51%Positive
FTSE 100	7,564.27	1.07%Positive
Nikkei 225	27,665.01	0.78%Negative

Delayed data (1h)

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Index	Last	% Change
S&P 500	4,027.81	1.42%Positive
Euro STOXX 50	4,231.27	1.51%Positive
FTSE 100	7,564.27	1.07%Positive
Nikkei 225	27,665.01	0.78%Negative

Share this page

Make smarter investment strategies
with in-depth news reports

Join our subscribers!

Algernon Pharmaceuticals Inc.

Valuation Measures4

Trading Information

Stock Price History

Share Statistics

Dividends & Splits

Financial Highlights

Fiscal Year

Profitability

Management Effectiveness

Income Statement

Balance Sheet

Cash Flow Statement

Psychedelics News and Psilocybin Investing

Major Holders

Breakdown

Search SEDAR Filings

Press Releases by Algernon Pharmaceuticals Inc.

Share this page

Make smarter investment strategies with in-depth news reports

Valuation Measures⁴

Make smarter investment strategies
with in-depth news reports